Mpox (monkeypox) vaccine Vaccine safety data Main navigation COVID-19 vaccines Influenza vaccines National Immunisation Program Schedule vaccines Mpox (monkeypox) vaccine Intradermal JYNNEOS Mpox (monkeypox) vaccine Subcutaneous JYNNEOS mpox (monkeypox) vaccine Mpox vaccine safety surveillance conducted by AusVaxSafety was completed on 17 April 2023. Data on this page will no longer be updated. Safety data collected from more than 15,000 JYNNEOS mpox vaccine recipients identified no safety issues in either administration method, intradermal and subcutaneous. The Therapeutic Goods Administration (TGA) continues to monitor the safety of mpox vaccines in Australia. Mpox vaccine safety data Click on the tiles below to view subcutaneous and intradermal mpox vaccine safety data. Intradermal JYNNEOS mpox (monkeypox) vaccine View the latest intradermal JYNNEOS mpox vaccine safety data here Subcutaneous JYNNEOS mpox (monkeypox) vaccine View the latest subcutaneous JYNNEOS mpox vaccine safety data here Vaccine safety data Main navigation COVID-19 vaccines Influenza vaccines National Immunisation Program Schedule vaccines Mpox (monkeypox) vaccine Intradermal JYNNEOS Mpox (monkeypox) vaccine Subcutaneous JYNNEOS mpox (monkeypox) vaccine News & events All news & events 14 September 2023 | News Vaxtracker wins Hunter New England Health Excellence Award 17 May 2023 | News Subcutaneous and intradermal administration of mpox vaccine well tolerated, AusVaxSafety study finds 10 May 2023 | News New bivalent BA.4/BA.5 COVID-19 booster vaccines well tolerated by Australians, new AusVaxSafety data show 20 April 2023 | News Influenza is back in Australia in 2023: Why a flu shot is so important, who is eligible and what to expect in the days following your vaccination